WILEX collaborates and has license agreements with a number of leading academic and clinical institutions as well as pharmaceutical companies in Europe and North America. The Company considers these relationships to be important to its ability to gain access to and exploit possible new developments within its business focus.
- Bayer Corporation, Tarrytown, NY, USA, 2001: Licensing agreement on MN/CA IX antigen of the RENCAREX® antibody. (Press Release)
- Centocor Inc., Malvern, USA/University of Leiden, Netherlands, 1999: Licensing of G250/Girentuximab antibody. (Press Release)
Licence agreements are an important part of the Company’s commercialisation strategy. You will find details of existing partnerships or options for further cooperations here.